In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Stacie Hudgens, Chief Scientific and Strategy Officer at Clinical Outcome Solutions, to discuss whether the field of clinical outcome assessment has started sacrificing “good for perfect.” Together, they explore the role of regulatory guidance and clinical development timelines, specifically the role of measurement science in already tight development timelines, when to modify a legacy instrument versus build something new, and why getting measurement scientists involved early is the key to a successful COA strategy.
In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Dr. Kate Williams, Director of Patient-Centred...
In this episode, host Mark Wade is joined by Bill Byrom, the VP of Product Intelligence and Positioning at Signant Health, as they explore...
In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Stacey Higgins, Associate Director, COA &...
